Les Entreprises Du Medicament
Les Entreprises Du Medicament, commonly referred to as LEDM, is a prominent business association based in France. Headquartered in Paris, the organisation primarily operates across the European pharmaceutical and healthcare sectors, supporting companies involved in medication development, manufacturing, and distribution. Founded in the early 2000s, LEDM has established itself as a key industry advocate, fostering collaboration and innovation within the pharmaceutical community.
The association’s core services include industry advocacy, regulatory support, and facilitating networking opportunities for members. Its members benefit from specialised insights into market trends, compliance requirements, and research advancements. Recognised for its influential role in shaping pharmaceutical policies, Les Entreprises Du Medicament holds a notable position within the European healthcare industry, contributing to the advancement of safe and effective medication practices.
+14 vs industry average
Les Entreprises Du Medicament’s score of 34 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Les Entreprises Du Medicament?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Business Associations has below-average carbon intensity
Industry performance
The Business Associations industry has reduced its overall emissions by 37% since 2018
Reported emissions
No reported emissions data is available for Les Entreprises Du Medicament yet.
Les Entreprises Du Medicament's reported carbon emissions
Les Entreprises Du Medicament, based in France and operating within the Business Associations industry, has established significant climate commitments. The organisation aims for a 50% reduction in greenhouse gas emissions across its entire value chain by 2030, using 2015 as a baseline. This target includes a 50% reduction for Scope 1 and Scope 2 emissions by the same year. Additionally, a specific commitment from 2021 to 2030 targets a 50% reduction in CO2 emissions for both Scope 1 and 2, encompassing both the production and consumption of medicines. This goal aligns with an SBTi target of 37.7%. While specific absolute emissions data for Les Entreprises Du Medicament is not available, these targets demonstrate a clear strategy towards decarbonisation.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Les Entreprises Du Medicament’s Climate Goals (2030 & 2050)
6 goals2050
80% reduction in Scope 2
The emissions saved by the initiatives and operational changes tested in this study were not sufficient for reaching the target of 80% reduc…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 6 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project